Daiichi Sankyo is participating in Access Accelerated, which was established in 2017 by pharmaceutical companies from Japan, the United States, and Europe in partnership with the World Bank and the Union for International Cancer Control, among others, with the purpose of improving prevention, diagnosis, treatment, and other aspects of NCDs* in low-income and lower-middle income countries.

Access Accelerated is working to improve access to healthcare in target countries to achieve one of the targets of Goal 3 of the SDGs: “By 2030, reduce by one third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being.”
^*Non-Communicable Diseases  such as cancer, cardiovascular disease, chronic respiratory disease, and diabetes.

Access Accelerated’s activities are summarized in annual reports. In May 2023, a report summarizing activities from its establishment to 2022 (Phase I - II) was published.
For more information on Access Accelerated’s activities, please visit the following website:

• Access Accelerated
• AA-WB M&E 2023 Report